Dr Ralph Ernest Harold, MD | |
22710 Sw Hampton Ct, Blue Springs, MO 64015-9616 | |
(816) 808-2465 | |
(913) 562-5004 |
Full Name | Dr Ralph Ernest Harold |
---|---|
Gender | Male |
Speciality | Ophthalmology |
Location | 22710 Sw Hampton Ct, Blue Springs, Missouri |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1720127996 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207W00000X | Ophthalmology | 2004003807 (Missouri) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Ralph Ernest Harold, MD 22710 Sw Hampton Ct, Blue Springs, MO 64015-9616 Ph: (816) 808-2465 | Dr Ralph Ernest Harold, MD 22710 Sw Hampton Ct, Blue Springs, MO 64015-9616 Ph: (816) 808-2465 |
News Archive
A study published in the September 2006 issue of the journal Intelligence analyzed 145 items from the Scholastic Assessment Test (SAT) in 100,000 17- to 18-year-olds and found a male IQ advantage of 3.63 points.
One of the enduring mysteries of President Obama's health law is how its spending constraints and payroll tax hikes on high earners can be used to shore up Medicare finances and at the same time pay for a massive new entitlement program. Isn't this double counting?
1 in 6 British couples now face problems conceiving, so maximising the chances of natural conception by identifying precisely when ovulation occurs is critical.
In an international study, Mayo Clinic researchers and collaborators have identified genetic markers that may help in identifying individuals who could benefit from the alcoholism treatment drug acamprosate. The findings, published in the journal Translational Psychiatry, show that patients carrying these genetic variants have longer periods of abstinence during the first three months of acamprosate treatment.
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received funding to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of IPF, which affects more than 100,000 Americans.
› Verified 1 days ago
Dr. Nathan C Hamaker, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1613 S 7 Hwy, Blue Springs, MO 64014 Phone: 816-478-1230 Fax: 816-478-4413 |